Urgent(R) PC and Macroplastique(R) Featured in Numerous International Continence Society Meeting Sessions
06 Ottobre 2009 - 12:30PM
PR Newswire (US)
MINNEAPOLIS, Oct. 6 /PRNewswire-FirstCall/ -- Uroplasty, Inc.
(AMEX:UPI), a medical device company developing, manufacturing and
marketing innovative proprietary products for the treatment of
voiding dysfunctions, today highlighted presentations, workshops
and posters focused on its products at the 39th Annual Meeting of
the International Continence Society Meeting (ICS), September 29 -
October 3 in San Francisco. Both Uroplasty's Urgent® PC and
Macroplastique® were highlighted. Urgent® PC presentations and
posters included: -- "Six and 12 Month Results from OrBIT Trial
Comparing Percutaneous Tibial Nerve Stimulation (PTNS) vs.
Extended-Release Tolterodine," a poster presentation by Kenneth M.
Peters, M.D., Chairman of the Department of Urology at Beaumont
Hospital in Royal Oak, Mich., demonstrated Urgent® PC has
comparable performance to the leading prescribed overactive bladder
drug and excellent durability through 12 months of follow-up. To
assess the longer term effectiveness of Urgent PC, 30 and 25
patients in the OrBIT study completed voiding diaries at 6 and 12
months respectively. The patients showed sustained improvement with
self-assessment of 93.8 percent improvement at 6 months and 96
percent at 12 months. Investigators' assessments of improvement
were similar, 96.9 percent and 96 percent. There were no serious
adverse events or device malfunctions. -- "Percutaneous Tibial
Nerve Stimulation: Efficacy with Patients also Taking
Anticholinergics," a poster presented by Leslie Wooldridge, GNP, of
Mercy Health Partners Bladder Control Clinic, Muskegon, Mich.,
found Urgent PC to be an effective adjunct to anticholinergic
medications or replacement for medications used to treat overactive
bladder symptoms. -- "Is Cost the Achilles Heel of Posterior Tibial
Nerve Stimulation? A Cost Minimisation Comparison with
Antimuscarinic Therapy in the Management of OAB," a poster
presented by Dudley Robinson, M.D., of King's College Hospital in
London, England, suggesting that while drug therapy is initially
less expensive than Urgent PC, there is a trend to reduced costs in
Urgent PC over time as the initial equipment costs are offset,
suggesting that therapy may become increasingly cost effective over
the long term. Urgent PC was highlighted in workshops entitled: --
"Update on the Management of Overactive Bladder Syndrome," chaired
by Hashim Hashim, M.D., Bristol Urological Institute, Bristol,
England -- "Treatment of LUT Dysfunction by Means of Electrical
Stimulation: Scientific Foundation and Clinical Applications,"
chaired by John Heesakkers, M.D. of Radboud University Nijmegen,
The Netherlands. "The clinical data presented at the 2009 Annual
ICS Meeting continues to add to the existing body of clinical
evidence from leading physicians highlighting the ease-of-use,
safety and efficacy of our Urgent PC system for the treatment of
urinary frequency, urinary urgency and urge incontinence, symptoms
associated with overactive bladder," said David Kaysen, President
and CEO of Uroplasty, Inc. "This represents still further data that
we will present to the medical directors of U.S. payers as part of
our ongoing effort to continue to build awareness for reimbursement
and apply for a unique CPT code for PTNS here in the U.S. In
addition to Urgent PC, Macroplastique, our 'Gold Standard' bulking
agent for the treatment of adult female stress urinary incontinence
received attention and is continuing to find a larger and larger
receptive audience." Several Macroplastique presentations were also
made at the ICS annual meeting: -- "Redefining the Success Rate of
Bulking Agents: Role of Composite Endpoints," a poster by Arasee
Renganathan, M.D. of King's College Hospital in London, England,
which found 80 percent of women considered themselves cured with
Macroplastique and 75 percent were considered cured by objective
standards. In addition to this presentation, Macroplastique was
highlighted in workshops entitled: -- "Practical Aspects of Bulking
Agents in the Treatment of Pelvic Floor Dysfunction," chaired by
Sherif Mourad, M.D. of Ain Shams University, Cairo, Egypt. --
"Urethal Bulking Agents for the Minimally Invasive Treatment of
Stress Urinary Incontinence," chaired by Linda Cardozo, M.D. of
King's College Hospital in London, England. "The 39th Annual ICS
Meeting represents another significant success for Uroplasty,"
concluded Mr. Kaysen. "Urgent PC and Macroplastique were the
subject of numerous positive discussions in diverse venues. These
presentations resulted in enhanced interest in our products that
resulted in more physician visits to our exhibit booth in turn
generating a large number of sales leads." About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with
wholly-owned subsidiaries in The Netherlands and the United
Kingdom, is a medical device company that develops, manufactures
and markets innovative proprietary products for the treatment of
voiding dysfunctions. Our primary focus is the commercialization of
our Urgent® PC system, which we believe is the only FDA-approved
non-surgical neurostimulation therapy for the treatment of urinary
symptoms often associated with overactive bladder (OAB). We also
offer Macroplastique® Implants, a urethral bulking agent for the
treatment of adult female stress urinary incontinence. Please visit
Uroplasty, Inc. at http://www.uroplasty.com/. Forward-Looking
Information This press release contains forward-looking statements,
which reflect our best estimates regarding future events and
financial performance. These forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially from our anticipated results. We discuss in
detail the factors that may effect the achievement of our
forward-looking statements in our Annual Report on Form 10-K filed
with the SEC. Further, we cannot assure you that we will timely
obtain, or even succeed at all at obtaining, a specific "listed"
CPT reimbursement code from the AMA for Urgent PC treatments, and
that even if we succeed at obtaining a CPT code third-party payors
will provide or continue to provide coverage and reimbursement, or
reimburse the providers an amount sufficient to cover their costs
and expenses. We further cannot assure that reimbursement or other
issues will not further impact our fiscal 2010 results. For Further
Information: Uroplasty, Inc. EVC Group David Kaysen, President and
CEO, or Doug Sherk (Investors) Medi Jiwani, Vice President, CFO,
415.896.6820 and Treasurer, Chris Gale (Media) 952.426.6140
646.201.5431 DATASOURCE: Uroplasty, Inc. CONTACT: David Kaysen,
President and CEO, or Medi Jiwani, Vice President, CFO, and
Treasurer, both of Uroplasty, Inc., +1-952-426-6140; or Investors,
Doug Sherk, +1-415-896-6820, or Media, Chris Gale, +1-646-201-5431,
both of EVC Group, for Uroplasty, Inc. Web Site:
http://www.uroplasty.com/
Copyright
Grafico Azioni Uroplasty (AMEX:UPI)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Uroplasty (AMEX:UPI)
Storico
Da Mag 2023 a Mag 2024